LVI is an independent Prognostic Predictor of oncologic outcomes after RC for patients with UCB and SCC of the urinary bladder.
LVI may have greater prognostic significance in patients with SCC compared to UCB.
The incorporation of LVI into prognostic models after RC may help improve stratification and identification of high-risk patients who may benefit from multimodal treatment approaches.